Anthropic and OpenEvidence to provide free, region-adapted medical AI to about 100 low- and middle-income countries

# What happened Anthropic and OpenEvidence announced a collaboration to deliver AI-powered clinical decision support to clinicians in roughly 100 low- and middle-income countries. The offering is a specialized version of OpenEvidence's platform, and it will be provided free to healthcare providers in those countries.

# What the service does OpenEvidence answers clinicians' questions by drawing on peer-reviewed medical research and treatment guidelines. In the U.S. and Canada the platform is already available free to clinicians. Under this initiative, Anthropic will provide the AI back-end and OpenEvidence will adapt the product for specific regional needs, taking into account local disease patterns, diagnostic resources, and available treatments.

# Where it will go first The rollout list provided by OpenEvidence includes countries such as Uganda, Angola, Sudan, Haiti, and Mongolia, and totals about 100 countries. The companies say the product is being tailored for settings where limited access to medical literature and specialist expertise can impair patient care.

# How adaptation is described

# Scale and current usage OpenEvidence reported large use in the United States: in August alone, U.S. clinicians consulted the platform 42 million times. The company also said that in 2026 several hundred million Americans will have been treated by a doctor who used OpenEvidence to help guide care. Anthropic and OpenEvidence did not disclose any financial terms for the collaboration.

# Operational note OpenEvidence's founder Daniel Nadler framed the effort around geographical equity in access to medical knowledge. The companies noted that while some facilities may lack consistent electricity, many clinicians have smartphones, which can serve as the primary access point for the service.

# Broader context

# What's left unclear The companies did not provide financial details, nor did they specify an exact rollout timeline for all countries on the list. The announcement also did not detail how local regulatory approvals, language localization, training for clinicians, or monitoring for safety and accuracy will be managed at scale.

# Why it matters to clinicians and health systems If the platform performs as described, clinicians in resource-constrained settings could gain faster access to up-to-date, guideline-based answers to clinical questions. That could shorten the time needed to find relevant evidence and support decision-making when specialist consultation or full-text literature access is limited. However, successful impact depends on accurate localization, reliable connectivity or offline access strategies, clinician trust, and ongoing evaluation against local outcomes.